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ABSTRACT
MTUS1 (microtubule-associated tumor suppressor 1)
has been identiﬁed that can function as a tumor sup-
pressor gene in many malignant tumors. However, the
function and mechanisms underlying the regulation of
MTUS1 are unclear. In the present study, we reported
that miR-19a and miR-19b (miR-19a/b) promote prolifer-
ation and migration of lung cancer cells by targeting
MTUS1. First, MTUS1 was proved to function as a tumor
suppressor in lung cancer and was linked to cell prolif-
eration and migration promotion. Second, an inverse
correlation between miR-19a/b expression and MTUS1
mRNA/protein expression was noted in human lung
cancer tissues. Third, MTUS1 was appraised as a direct
target of miR-19a/b by bioinformatics analysis. Fourth,
direct MTUS1 regulation by miR-19a/b in lung cancer
cells was experimentally afﬁrmed by cell transfection
assay and luciferase reporter assay. Finally, miR-19a/b
were shown to cooperatively repress MTUS1 expression
and synergistically regulate MTUS1 expression to pro-
mote lung cancer cell proliferation and migration. In
conclusion, our ﬁndings have provided the ﬁrst clues
regarding the roles of miR-19a/b, which appear to func-
tion as oncomirs in lung cancer by downregulating
MTUS1.
KEYWORDS microRNA, MTUS1, miR-19a/b,
lung cancer, proliferation, migration
INTRODUCTION
All over the world, lung cancer has been the leading cause of
cancer-related death (Ramalingam et al., 1998). The 56% of
lung cancers are diagnosed during the late stages of disease
while the early stages of disease are usually asymptomatic;
only 15% of cases can be diagnosed during a local stage
(Siegel et al., 2012). Many carcinogenic factors, such as
smoking, genetic mutations and declining immune function,
may increase the risk of developing lung cancer. Under-
standing the molecular mechanism of lung cancer is the
hinge of identifying new therapeutic targets and designing
new drugs. However, the exact mechanisms underlying the
development of lung cancer remain complex and poorly
understood. These obstacles underscore the need for in-
depth exploration for genes that are aberrantly expressed
during lung carcinogenesis, and the need for intensive
investigations of the roles of these genes in tumor biology.
MTUS1 (microtubule-associated tumor suppressor 1
gene), also known as mitochondrial tumor suppressor gene
1, is localized to chromosome 8p22 and comprises 17 exons
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(Molina et al., 2011). MTUS1 encodes a family of angiotensin
II (AT2) receptor-interacting proteins (ATIP), and by alter-
native exon utilization in this gene, 5 known transcript vari-
ants are coded to 5 different protein isoforms of ATIP (ATIP1,
ATIP2, ATIP3a, ATIP3b, and ATIP4) (Di Benedetto et al.,
2006). The 5 ATIP protein exhibit distinct motifs in their
amino-terminal portion that determine whether they localize
to the cell membrane, the cytosol or the nucleus (ATIP1,
ATIP3 and ATIP4 localize to the cytosol, nucleus and plasma
membrane, respectively). MTUS1 downregulation or loss
has been documented in many types of cancer, including
colon, oral, gastric, and bladder cancer (Zuern et al., 2010;
Ding et al., 2012; Xiao et al., 2012; Li et al., 2014a). Although
several papers regarding the relationship between MTUS1
gene expression and cancer have been published, the roles
of MTUS1 in the development of human cancers (especially
lung cancer) remain unclear. The target of this study was to
evaluate the association between MTUS1 gene expression
and lung cancer and to identify the molecular pathways
associated with MTUS1 regulation.
Over the past years, a class of small, single-stranded,
non-coding RNAs, known as microRNAs (miRNAs), have
emerged as major regulators of the development of human
cancers, including lung cancer (Guz et al., 2014; Kang and
Lee, 2014). Downregulation of tumor-suppressor miRNAs
(targeting oncogenes) and upregulation of oncogenic miR-
NAs (targeting tumor suppressor genes) lead to cancer cell
dysfunction, including malignant proliferation, invasion, and
metastasis (Calin and Croce, 2006; Ma and Weinberg, 2008;
Nicoloso et al., 2009). The miR-17-92 miRNA cluster is one
of the best characterized groups of miRNA oncogenes, and
genomic ampliﬁcation or aberrant expression of these miR-
NAs is frequently observed in a variety of tumor types (Olive
et al., 2013; Guinot et al., 2016; Robaina et al., 2016). As
members of the miR-17-92 cluster, miR-19a and miR-19b
(miR-19a/b) usually function as oncogenes in many types of
cancer, including gastric cancer (Lu et al., 2015), pancreatic
cancer (Wang et al., 2016), and breast cancer (Li et al.,
2014b). However, the molecular basis underlying the con-
tributions of miR-19a/b to the development of lung cancer
remains to be elucidated.
In this study, we found that MTUS1 functions as a tumor
suppressor in lung cancer cells. Next, we identiﬁed miR-19a/b
as a potential regulator ofMTUS1using bioinformatics analysis
and experimentally conﬁrmed that MTUS1 is directly regulated
by miR-19a/b in lung cancer cells. Finally, we showed that
MTUS1 is synergistically suppressed bymiR19a/b, resulting in
lung cancer cell proliferation and migration.
RESULTS
MTUS1 functions as a tumor suppressor in lung cancer
cells
We ﬁrst conﬁrmed the expression of MTUS1 in human lung
cancer tissues (The clinical features of the patients are listed
in Table S1). After measuring the levels of MTUS1 protein
expression in 9 pairs of lung cancer tissue samples and
corresponding normal adjacent tissue samples, we found
that MTUS1 protein levels were signiﬁcantly lower in lung
cancer tissues than in normal tissues (Fig. 1A and 1B).
Correspondingly, MTUS1 mRNA levels were consistently
downregulated in lung cancer tissues compared with normal
tissues (Fig. 1C).
We next evaluated the biological functions of MTUS1 in
lung cancer cell line A549. Normal human bronchial
epithelial HBE was used as normal control. We designed 3
siRNA sequences targeting different human MTUS1 cDNA
sites and transfected them into A549 cells (Fig. S1A). Then,
we performed cell viability assay to determine the effects of
MTUS1 on the proliferation of A549 and HBE. MTUS1
knockdown with siRNA signiﬁcantly promoted HBE cell
proliferation (Fig. 1D) and MTUS1 overexpression with
MTUS1 vector inhibited A549 cell proliferation (Fig. 1E). We
also used wound healing and transwell assays to investigate
the effects of MTUS1 on the migration of A549 and HBE.
HBE transfected with MTUS1 siRNA exhibited increased
migration but A549 transfected with MTUS1 vector exhibited
decreased migration (Fig. 1F and 1G). These results sug-
gest that MTUS1 functions as a tumor suppressor and can
suppress lung cancer cell proliferation and migration.
Identiﬁcation of conserved miR-19a/b target sites
within the 3′-UTR of MTUS1
The mechanism underlying MTUS1 downregulation in lung
cancer tissues remains largely unknown. One important
cFigure 1. MTUS1 functions as a tumor suppressor in
lung cancer cells. (A and B) Western blot analysis of
MTUS1 protein levels in 9 pairs of lung cancer tissue (LCT)
samples and adjacent noncancerous tissue (NCT) sam-
ples. (A) Representative image; (B) quantitative analysis.
(C) Quantitative RT-PCR analysis of the relative expres-
sion levels of MTUS1 mRNA in 9 pairs of NCT and LCT
samples. (D) Cell proliferation assay was performed 12,
24, 36, 48, 60, and 72 h after transfection of equal doses of
MTUS1 siRNA/scrambled control siRNA into HBE cells.
(E) Cell proliferation assay was performed 12, 24, 36, 48,
60, and 72 h after transfection of equal doses of MTUS1
vector/control vector into A549 cells. (F) Wound healing
assays were performed 24 h after transfection of equal
doses of MTUS1 siRNA/scrambled control siRNA into
HBE cells or MTUS1 vector/control vector into A549 cells.
Left panel: representative image; right panel: quantitative
analysis of wound closure rates. (G) Transwell assays
were performed 24 h after transfection of equal doses of
MTUS1 siRNA or scrambled control siRNA into HBE cells
or MTUS1 vector/control vector into A549 cells. Left panel:
representative image; right panel: quantitative analysis.
*, P < 0.05; **, P < 0.01; ***, P < 0.001.
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mode of gene regulation is miRNA-mediated post-tran-
scriptional mRNA transcript repression. Therefore, miRNAs
likely play a biologically relevant role in regulating MTUS1
expression in lung cancer. TargetScan, miRanda, and PicTar
were used in combination to identify potential miRNAs tar-
geting MTUS1. MiR-19a/b were identiﬁed as candidate
regulatory miRNAs of MTUS1 and were selected for further
experimental veriﬁcation. The predicted interactions
between miR-19a/b and their target sites in the MTUS1
3′-UTR are illustrated in Fig. 2A. One overlapping hybrid
between the MTUS1 3′-UTR and miR-19a or miR-19b was
identiﬁed. The minimum free energy values of these
hybridizations were −28.7 and −30.2 kcal/mol, which are well
within the range of genuine miRNA-target pairs. Moreover,
there was perfect base-pairing between the seed regions
(The core sequences that encompass the ﬁrst 2–8 bases of
the mature miRNA) and cognate targets, and the miR-19a/b
binding sequences in the MTUS1 3′-UTR were highly con-
served across species.
Detection of an inverse correlation between miR-19a/b
and MTUS1 levels in lung cancer tissues
Because miRNAs generally exhibit expression patterns that
contrast with those of their targets (Ambros, 2004; Bartel,
2004; He and Hannon, 2004), we investigated whether
miR-19a/b expression levels were inversely correlated with
MTUS1 expression levels in lung cancer. After determining
the levels of miR-19a/b in 9 pairs of lung cancer tissues and
corresponding normal adjacent tissues, we showed that
miR-19a/b expression levels were consistently upregulated
in lung cancer tissues (Fig. 2B). The inverse correlation
between miR-19a/b levels and MTUS1 protein/mRNA levels
was illustrated further using Pearson’s correlation scatter
plots (Fig. 2C). Based on the results of the computational
prediction and the detection of an inverse correlation
between miR-19a/b expression and MTUS1 expression
in vivo, it is very likely that miR-19a/b are involved in MTUS1
post-transcriptional regulation.
Validation of MTUS1 as a direct target of miR-19a/b
The correlation between miR-19a/b and MTUS1 was
examined further by evaluating MTUS1 expression in three
lung cancer cell lines (A549, H1975, and HCC827) in the
setting of miR-19a/b overexpression or knockdown. In these
experiments, miR-19a/b overexpression was achieved by
transfecting cells with pre-miR-19a/b (synthetic RNA
oligonucleotides mimicking miR-19a/b precursors), whereas
miR-19a/b knockdown was achieved by transfecting cells
with anti-miR-19a/b (chemically modiﬁed antisense oligonu-
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Figure 2. Inverse correlation between miR-19a/b and MTUS1 levels in lung cancer tissue samples. (A) Schematic description
of the hypothetical duplexes formed by interactions between the MTUS1 3′-UTR (top) and miR-19a/b (bottom). The predicted free
energy value of each hybrid is indicated. The seed recognition sites are denoted, and all nucleotides in these regions are highly
conserved across several species. (B) Quantitative RT-PCR analysis of miR-19a/b levels in 9 pairs of NCT and LCT samples.
(C) Pearson’s correlation scatter plot of the fold changes in miR-19a/b and MTUS1 protein/mRNA expression in lung cancer tissues.
*, P < 0.05; **, P < 0.01; ***, P < 0.001.
RESEARCH ARTICLE Yuanyuan Gu et al.









As anticipated, cellular miR-19a/b levels were signiﬁcantly
increased in A549, H1975, and HCC827 cells when these
cells were transfected with pre-miR-19a/b, whereas
miR-19a/b levels were signiﬁcantly decreased when these
cells were transfected with anti-miR-19a/b (Fig. S2A and
S2B). Consequently, MTUS1 protein expression was signif-
icantly inhibited by the introduction of miR-19a/b in A549,
H1975 and HCC827 cells, while MTUS1 protein expression
was signiﬁcantly increased by the introduction of anti-miR-
19a/b in these cells (Fig. 3A and 3B). To determine the level
at which miR-19a/b inﬂuenced MTUS1 expression, we
repeated the above experiments and examined MTUS1
mRNA expression after transfection. MTUS1 mRNA
expression was decreased by miR-19a/b overexpression
and increased by miR-19a/b knockdown in A549, H1975,
and HCC827 cells (Fig. 3C and 3D). These results are
consistent with the idea that animal miRNAs can decrease
gene expression levels by regulating mRNA splicing or
promoting mRNA degradation (Adams et al., 2014).
To determine whether the inhibitory effects exerted by
miR-19a/b on MTUS1 expression are mediated via binding
of miR-19a/b to their presumed target sites in the MTSU1
mRNA 3′-UTR, the entire MTSU1 3′-UTR containing the
presumed miR-19a/b binding sites was fused to a reporter
plasmid downstream of the ﬁreﬂy luciferase gene. The
resulting plasmid was transfected into A549 cells along with
a transfection control plasmid (β-gal) and pre-miR-19a/b,
anti-miR-19a/b or scrambled negative control RNAs. As
expected, miR-19a/b overexpression resulted in a ∼40%
reduction in luciferase reporter activity compared to cells
treated with the pre-miR control, whereas miR-19a/b inhibi-
tion resulted in a 1.5-fold increase in reporter activity com-
pared to cells transfected with the anti-miR control (Fig. 3E).
Furthermore, we induced point mutations into the corre-
sponding complementary sites in the MTUS1 3′-UTR to
eliminate the predicted miR-19a/b binding sites. This muta-
ted luciferase reporter was unaffected by miR-19a/b over-
expression or knockdown (Fig. 3E). This ﬁnding suggests
that the presumed binding sites strongly contribute to the
abovementioned miRNA-mRNA interactions. In conclusion,
these results suggest that miR-19a/b recognize and bind to
the 3′-UTR of the MTUS1 mRNA transcript and inhibit
MTUS1 translation.
As a single miRNA can target hundreds of genes, it is
necessary to determine whether the effects of miR-19a/b on
lung cancer cells are derived from miR-19a/b-mediated
MTUS1 suppression. To investigate whether the regulation
of cell proliferation, migration, and invasion by miR-19a/b is
executed through a MTUS1-dependent manner, we co-
transfected A549 cells with miR-19a/b mimic and the
MTUS1-overexpression vector. Compared with cells trans-
fected with miR-19a/b mimic and control vector, the cells
transfected with both miR-19a/b mimic and MTUS1 vector
exhibited a signiﬁcantly lower proliferation rate (Fig. S3A),
suggesting that miR-19a/b-resistant MTUS1 can attenuate
the proliferative effect of miR-19a/b on lung cancer cells.
Likewise, when A549 cells were simultaneously transfected
with miR-19a/b mimic and the MTUS1 vector, MTUS1 dra-
matically attenuated the promotive effect of miR-19a/b on
cell migration in transwell invasion assay and wound healing
assay (Fig. S3B and S3C). Taken together, these results
indicate that miR-19a/b may regulate the proliferation,
migration, and invasion of lung cancer cells through a
MTUS1-dependent manner.
Co-treatment with miR-19a/b synergistically suppresses
MTUS1 expression in lung cancer cells
MiR-19a/b belong to the same miRNA family and differ by
only a single nucleotide at position 11. Because miR-19a/b
display extensive sequence homology, they are thought to
possess overlapping targets and have redundant functions.
One goal of this study was to determine whether miR-19a/b
function individually or synergistically. Equal amounts of pre-
miR-19a (100 pmol), pre-miR-19b (100 pmol) or pre-miR-
19a/b (50 pmol each) were transfected into A549 cells to
overexpress miR-19a and/or miR-19b, respectively, and the
reductions in MTUS1 levels were measured. Co-treatment
with pre-miR-19a and pre-miR-19b successfully increased
miR-19a/b levels (Fig. S2C and S2D) and enhanced MTUS1
protein and mRNA suppression compared to treatment with
either pre-miR-19a or pre-miR-19b alone (Fig. 4A–C). These
results indicated that the suppressive effects of miR-19a/b
on MTUS1 protein and mRNA expression were not an indi-
vidual effects but synergistic effects. Likewise, co-treatment
with anti-miR-19a and anti-miR-19b successfully decreased
miR-19a/b levels (Fig. S2C and S2D). While MTUS1 protein
and mRNA expression was signiﬁcantly increased in A549
cells transfected with anti-miR-19a (100 pmol) or anti-miR-
19b (100 pmol), the greatest increase in expression occurred
when anti-miR-19a and anti-miR-19b (50 pmol each) were
transfected into A549 cells simultaneously (Fig. 4A–C).
These results conﬁrmed the synergistic effects of miR-19a/b
on MTUS1 expression in lung cancer cells.
The roles of miR-19a/b in regulating MTUS1 in lung
cancer cells
To investigate the cellular phenotypes triggered bymiR-19a/b-
mediated MTUS1 downregulation, A549 cells were trans-
fected with either pre-miR-19a/b or anti-miR-19a/b and then
analyzed regarding changes in cell proliferation andmigration.
Cell viability assay showed that cell proliferation was signiﬁ-
cantly increased in A549 cells transfectedwith pre-miR-19a/b,
which conﬁrmed the hypothesis that miR-19a/b function as
oncogenic miRNAs; in contrast, miR-19a/b knockdown had
the opposite effect on A549 cell proliferation (Fig. 4D and 4E).
Thus, the cell proliferation promoted by MTUS1 knockdown
was similar to that elicited by miR-19a/b overexpression,
indicating that miR-19a/b and MTUS1 exert contrasting
effects on cell proliferation. Interestingly, although individual
MiR-19a/b regulate MTUS1 in lung cancer RESEARCH ARTICLE
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miR-19a or miR-19b overexpression/knockdown increases/
decreases cell proliferation, simultaneous introduction/re-
duction of miR-19a and miR-19b exerted synergistic effects
with respect to cell proliferation promotion/suppression com-
pared to the effects exerted by miR-19a or miR-19b alone
(Fig. 4D and 4E). These results suggest that miR-19a/b syn-
ergistically accelerate lung cancer cell proliferation. Further-
more, we evaluated the effects of miR-19a/b on lung cancer
cell migration using wound healing and Transwell assays.
During wound healing assay, more A549 cells migrated to the
scratch in the cell monolayer when these cells were trans-
fected with pre-miR-19a/b, while A549 cell mobility was sig-
niﬁcantly inhibited by anti-miR-19a/b transfection (Fig. 4F and
4G). In addition, Transwell assay revealed that the percentage
of migrated cells was signiﬁcantly higher among A549 cells
transfected with pre-miR-19a/b and signiﬁcantly lower among
cells transfected with anti-miR-19a/b (Fig. 4H and 4I). There-
fore, miR-19a/b and MTUS1 exerted opposing effects on cell
migration. More importantly, both the wound healing and the
Transwell assays indicated that simultaneous introduction of
miR-19a andmiR-19b exerted synergistic effects with respect
to the promotion of cell migration compared to the effects
exerted by miR-19a or miR-19b alone and that simultaneous
inhibition of miR-19a and miR-19b decelerated cell migration
more than inhibition of either miRNA alone (Fig. 4F–I). Taken
together, our ﬁndings indicate that because miR-19a/b and
MTUS1 exhibit contrasting expression patterns and exert
contrasting biological effects in lung cancer cells, it is very
possible that miR-19a/b synergistically modulate cell prolif-
eration andmigration in lung cancer cells by silencingMTUS1.
DISCUSSION
MTUS1 was ﬁrst identiﬁed as a tumor suppressor gene
located on chromosome 8p21.3-22 in 2003, and it is also
known as ATIP (AT2-receptor interacting protein), MTSG1
(mitochondrial tumor suppressor gene 1) GK1, and ATBP50
(Kinjo et al., 2000; Seibold et al., 2003; Wruck et al., 2005).
The MTUS1 gene contains 17 coding exons distributed over
112 kb of genomic DNA. Alternative exon usage enables the
generation of ﬁve transcripts (ATIP1, ATIP2, ATIP3a,
ATIP3b, and ATIP4), each exhibiting different tissue distri-
butions (Di Benedetto et al., 2006; Yu et al., 2009). All of
these transcripts share a common 118 amino acid AT2-re-
ceptor interacting domain (ID), which suggests that all 5
MTUS1 transcripts interact with the AT2-receptor and induce
atypical signal transduction pathways including at least three
intracellular cascades involving protein phosphatase acti-
vation, nitric oxide regulation, and phospholipase A2 stimu-
lation (Knowle et al., 2000). Additionally, recent studies have
shown that MTUS1 loss or downregulation is associated with
enhanced tumor proliferation, poor tumor differentiation, and
poor prognosis in bladder cancer (Xiao et al., 2012), gastric
cancer (Li et al., 2014a), salivary adenoid cystic carcinoma
(Zhao et al., 2015), and other cancers (Louis et al., 2010;
Louis et al., 2011; Ding et al., 2012; Varghayee et al., 2015).
In addition, MTUS1 has been shown to interfere with acti-
vation of the ERK2 pathway and to inhibit proliferation of
cells stimulated with growth factors, such as insulin, bFGF,
PDGF, and EGF (Nouet et al., 2004; Zuern et al., 2010).
Additionally, MTUS1 interference can result in inhibition of
EB1 turnover at microtubule plus ends (Velot et al., 2015).
Although several papers regarding the relationship between
MTUS1 gene expression and cancer have been published,
very little is known regarding the role and regulation of
MTUS1 in lung cancer. In this study, we measured MTUS1
protein and mRNA levels in human lung cancer tissues and
paired normal adjacent tissues and found that MTUS1 pro-
tein and mRNA levels were signiﬁcantly decreased in cancer
tissues, ﬁndings indicative of the potential tumor-suppressor
functions of MTUS1 in lung cancer. Furthermore, MTUS1
knockdown by siRNA promoted HBE cell proliferation and
migration. Similarly, MTUS1 overexpression by MTUS1
vector also suppressed A549 cell proliferation and migration.
These indicate that MTUS1 negatively modulates lung can-
cer cell proliferation and migration to exert its tumor sup-
pressor effects. However, the molecular mechanisms
underlying MTUS1 regulation remain unclear and must be
fully elucidated.
MiRNAs are important gene regulators and have been
shown to be involved in the initiation, development, and
metastasis of human cancers. During tumorigenesis, dys-
regulated miRNAs play either tumor-suppressor or onco-
genic roles, depending on the functions of their target genes.
Tumor-suppressor miRNAs usually repress oncogenes, and
oncogenic miRNAs usually silence tumor suppressor genes.
MiRNAs that are associated with human cancers are refer-
red to as oncomirs. Two of the most famous oncomirs,
miR-19a/b in the miR-17-92 miRNA cluster are involved in
regulating of a wide variety of human cancers. In this study,
we evaluated the expression patterns of miR-19a/b in lung
cancer tissues and observed that the expression levels of
b Figure 3. Direct regulation of MTUS1 expression by miR-
19a/b. (A and B) Western blot analysis of MTUS1 protein levels
in A549, H1975, and HCC827 cells transfected with pre-miR-
control, pre-miR-19a/b, anti-miR-control or anti-miR-19a/b.
(A) and (B) left: representative image; (A) and (B) right:
quantitative analysis. (C and D) Quantitative RT-PCR analysis
of MTUS1 mRNA levels in A549, H1975, and HCC827 cells
transfected with pre-miR-control, pre-miR-19a/b, anti-miR-con-
trol or anti-miR-19a/b. (E) Direct recognition of the MTUS1
3′-UTR by miR-19a/b. 293Tcells were co-transfected with ﬁreﬂy
luciferase reporters containing either wild-type (WT) or mutant
(Mut) miR-19a/b binding sites in the MTUS1 3′-UTR and pre-
miR-control, pre-miR-19a/b, anti-miR-control, or anti-miR-19a/b.
The cells were assayed using a luciferase assay kit 24 h after
transfection. The results are displayed as the ratio of ﬁreﬂy
luciferase activity in miR-19a/b-transfected cells to that in
control cells. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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both miR-19a and miR-19b were elevated in lung cancer
tissues compared with those in paired normal adjacent tis-
sues. We also showed that both miR-19a and miR-19b can
function as promoters of lung cancer cell proliferation and
migration. We found that miR-19a/b are co-upregulated in
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Figure 4. Effects of miR-19a/b on lung cancer cell proliferation and migration. (A and B) Western blot analysis of MTUS1
protein levels in A549 cells transfected with equal amounts of pre-miR-control (100 pmol), pre-miR-19a (100 pmol), pre-miR-19b (100
pmol) or pre-miR-19a/b (50 pmol each) or equal amounts of anti-miR-control (100 pmol), anti-miR-19a (100 pmol), anti-miR-19b (100
pmol) or anti-miR-19a/b (50 pmol each). (A) Representative image; B: quantitative analysis. (C) Quantitative RT-PCR analysis of
MTUS1 mRNA levels in A549 cells transfected with equal amounts of pre-miR-control (100 pmol), pre-miR-19a (100 pmol), pre-miR-
19b (100 pmol) or pre-miR-19a/b (50 pmol each) or equal amounts of anti-miR-control (100 pmol), anti-miR-19a (100 pmol), anti-miR-
19b (100 pmol) or anti-miR-19a/b (50 pmol each). (D and E) CCK-8 viability assays were performed 12, 24, 36, 48, 60, and 72 h after
transfection of equal amounts of pre-miR-control (100 pmol), pre-miR-19a (100 pmol), pre-miR-19b (100 pmol) or pre-miR-19a/b (50
pmol each) or equal amounts of anti-miR-control (100 pmol), anti-miR-19a (100 pmol), anti-miR-19b (100 pmol) or anti-miR-19a/b (50
pmol each) into A549 cells. (F and G) Wound healing assays were performed 24 h after transfection of equal amounts of pre-miR-
control (100 pmol), pre-miR-19a (100 pmol), pre-miR-19b (100 pmol) or pre-miR-19a/b (50 pmol each) or equal amounts of anti-miR-
control (100 pmol), anti-miR-19a (100 pmol), anti-miR-19b (100 pmol) or anti-miR-19a/b (50 pmol each) into A549 cells. Left panel:
representative image; right panel: quantitative analysis of wound closure rates. (H and I) Transwell assays were performed 24 h after
transfection of equal amounts of pre-miR-control (100 pmol), pre-miR-19a (100 pmol), pre-miR-19b (100 pmol) or pre-miR-19a/b (50
pmol each) or equal amounts of anti-miR-control (100 pmol), anti-miR-19a (100 pmol), anti-miR-19b (100 pmol) or anti-miR-19a/b (50
pmol each) into A549 cells. Left panel: representative image; right panel: quantitative analysis. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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allowed us to hypothesize that miR-19a/b may play impor-
tant roles in lung carcinogenesis. Interestingly, MTUS1 was
identiﬁed as a co-target of miR-19a/b by bioinformatics
analysis, and an inverse correlation between miR-19a/b
levels and MTUS1 levels was detected in lung cancer tis-
sues, indicating that miR-19a/b overexpression may play a
role in lung cancer progression by co-targeting MTUS1.
Thus, this study delineated a novel regulatory network
employing miR-19a/b and MTUS1 to regulate lung cancer
cell fates. MTUS1 modulation by miR-19a/b may explain why
miR-19a/b upregulation and MTUS1 downregulation during
lung carcinogenesis promote cancer progression. In future
studies, it will be important to determine how critical this
newly identiﬁed pathway is for lung tumorigenesis.
Many miRNAs work in conjunction with one another to
ﬁne-tune gene expression on a global level. Thus far, most
research regarding miRNAs has focused on the roles of
individual miRNAs in the regulation of speciﬁc genes. It is
important to study the cooperative roles played by multiple
miRNAs, as this may provide us with new and more com-
prehensive insights regarding miRNA regulation within the
cell. Studying the functions of miRNA family members
seems to be a promising means of deciphering the cooper-
ative effects of multiple miRNAs. MiRNA families comprise
multiple miRNAs exhibiting primary sequence similarity to a
speciﬁc seed sequence. Because this seed sequence plays
an important role to mRNA target speciﬁcity, miRNA family
members are thought to have extensive mRNA target over-
lap and redundant functions. One goal of this study was to
determine whether miR-19a/b function individually or syn-
ergistically. In this study, miR-19a/b were shown to partici-
pate in cooperative MTUS1 repression. Thus, co-treatment
with miR-19a and miR-19b synergistically promoted lung
cancer cell growth and migration compared with treatment
with miR-19a or miR-19b alone. These results indicate that
individual miRNA family members displaying co-expression
patterns can simultaneously and cooperatively repress a
given target mRNA. However, why cells use such sophisti-
cated and intricate mechanisms to regulate target gene
expression is a fascinating question. Perhaps co-regulation
serves as a fail-proof mode of miRNA regulation to ensure
that when one member of a miRNA pair is disabled by
mutations or dysfunction, the other is still available to per-
form its biological function. Cooperation between miRNA
family members thus represents an interesting area of study
that may change our perceptions regarding how miRNAs
mediate gene regulation.
CONCLUSIONS
In summary, this study not only elucidated the critical role of
MTUS1 as a tumor suppressor in lung cancer but also
explored the molecular mechanisms underlying MTUS1
regulation and identiﬁed miR-19a/b as direct upstream reg-
ulators of MTSU1 expression. This study has provided us
with insights regarding the molecular mechanisms underly-




Lung cancer tissue samples and paired normal adjacent tissue
samples were obtained from patients undergoing surgical proce-
dures at the Afﬁliated Drum Tower Hospital of Nanjing University
Medical School (Nanjing, China). Tissue fragments were immedi-
ately frozen in liquid nitrogen at the time of surgery and stored at
−80°C. The clinical features of the patients are listed in Table S1.
Cell culture
The human lung adenocarcinoma epithelial cell lines A549, H1975,
HCC827, and normal human bronchial epithelial cell line HBE were
purchased from the Shanghai Institute of Cell Biology, Chinese
Academy of Sciences (Shanghai, China). A549 cells were cultured
in DMEM (GIBCO, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum (FBS, GIBCO, Austria) in a humidiﬁed incubator
at 37°C with 5% CO2. H1975, HCC827, and HBE cells were cultured
in RPMI-1640 medium (GIBCO) supplemented with 10% FBS
(GIBCO) in a humidiﬁed incubator at 37°C with 5% CO2.
RNA isolation and quantitative RT-PCR
Total RNA was isolated from cultured cells or tissue samples using
TRIzol Reagent (Invitrogen, USA). The total RNA concentration was
determined using a BioPhotometer (Eppendorf, Germany). To
quantify MTUS1 and GAPDH mRNA, 1 μg of total RNA was reverse-
transcribed to cDNA using oligo(dT) 18 primers (TaKaRa, Dalian,
China) and avian myeloblastosis virus (AMV) reverse transcriptase
(TaKaRa, Dalian, China). The reaction conditions were as follows:
42°C for 60 min and 70°C for 10 min. Real-time PCR was then
performed using the RT product, SYBR Green dye (Invitrogen, USA)
and speciﬁc primers for MTUS1 and GAPDH (Table S2). The
reaction mixture was incubated at 95°C for 5 min, followed by 40
cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 1 min. After the
reactions, CT values were determined by setting a ﬁxed threshold.
The ratio of MTUS1 mRNA to GAPDH mRNA, which served as an
internal control, was calculated using the equation 2−△△CT, in which
△△CT = (CT MTUS1 − CT GAPDH)tumor − (CT MTUS1 − CT GAPDH)control.
MiRNA quantiﬁcation assay was performed using TaqMan miRNA
probes (Applied Biosystems, Foster City, CA, USA), according to the
manufacturer’s instructions. Brieﬂy, 1 μg of total RNA was reverse-tran-
scribed to cDNA using AMV reverse transcriptase and a stem-loop RT
primer (Applied Biosystems). The reaction conditions were as follows:
16°C for 30min, 42°C for 30min, and85°C for 5min.Real-timePCRwas
conducted using a TaqMan PCR kit and an Applied Biosystems 7500
Sequence Detection System (Applied Biosystems). The reaction was
incubated in a 96-well optical plate at 95°C for 10 min, followed by 40
cycles of 95°C for 15 s and 60°C for 1 min. All reactions were run in
triplicate. After the reaction, cycle threshold (CT) data were calculated
using ﬁxed threshold settings, and themeanCTwasdetermined from the
triplicate PCR results. The comparative CT method was used to
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determine relative miRNA levels. The ratio of miR-19a/b to U6, which
served an internal control, was calculated using the equation 2−△△CT, in
which △△CT = (CT miR-19a/b − CT U6)tumor − (CT miR-19a/b − CT U6)control.
Plasmid construction and siRNA interference assay
Mammalian expression plasmids designed to speciﬁcally express
the full-length open reading frame (ORF) of the human MTUS1 gene
were purchased from Genescript (Nanjing, China). An empty plas-
mid served as a negative control (control vector). Three siRNAs
targeting different sites of the human MTUS1 were designed and
synthesized by Invitrogen (Carlsbad, CA, USA). A scrambled siRNA
(Invitrogen) was included as a negative control. siRNAs were
transfected into A549 cells using Lipofectamine 2000 (Invitrogen,
Carlsbad, Calif), according to the manufacturer’s instructions. Total
RNA or protein was isolated 48 h after transfection. MTUS1 mRNA
and protein expression levels were assessed by quantitative RT-
PCR and Western blotting, respectively.
MiRNA overexpression and knockdown
MiRNA overexpression was achieved by transfecting cells with a
miRNA mimic, whereas knockdown was achieved by transfecting
cells with a miRNA inhibitor. Synthetic RNA molecules, including
pre-miR-19a and pre-miR-19b (miRNA mimics), anti-miR-19a and
anti-miR-19b (miRNA inhibitors), and scrambled negative control
RNAs (pre-miR-control and anti-miR-control), were purchased from
GenePharma (Shanghai, China). A549, H1975, and HCC827 cells
were seeded in 6-well plates and transfected with Lipofectamine
2000 on the following day, when the cells were approximately 80%
conﬂuent. For miRNA overexpression, equal amounts of pre-miR-
19a (100 pmol), pre-miR-19b (100 pmol) or pre-miR-19a/b (50 pmol
each) were used. For miRNA knockdown, equal amounts of anti-
miR-19a (100 pmol), anti-miR-19b (100 pmol) or anti-miR-19a/b (50
pmol each) were used. After 6 h, the medium was changed to
DMEM or RPMI-1640 supplemented with 2% FBS. The cells were
harvested 48 h after transfection for total RNA or protein isolation,
respectively.
Luciferase reporter assay
The entire 3′-untranslated region (3′-UTR) of the human MTUS1 was
ampliﬁed by PCR using human genomic DNA as a template. The
PCR products were inserted into the p-MIR-reporter plasmid (Am-
bion, Austin, TX, USA). The insertion was conﬁrmed to be correct by
DNA sequencing. To test binding speciﬁcity, the sequences that
interact with the seed sequence of miR-19a/b were mutated (from
TTGCAC to AACGTG), and the mutant MTUS1 3′-UTR was inserted
into an equivalent luciferase reporter plasmid. For the luciferase
reporter assays, 293T cells were seeded in 24-well plates and co-
transfected with 0.5 μg of ﬁreﬂy luciferase reporter plasmid, 0.5 μg of
β-galactosidase (β-gal) expression plasmid (Ambion,Austin, Tex),
and equal amounts (25 pmol) of miR-19a/b mimics, inhibitors, or
scrambled negative control RNAs using Lipofectamine 2000 (Invit-
rogen). The β-gal plasmid was used as a transfection control. Cells
were harvested 24 h after transfection and analyzed for luciferase
activity using a luciferase assay kit (Promega, Madison, WI, USA).
Protein isolation and Western blotting
Cells or tissues were lysed in a RIPA lysis buffer (50 mmol/L Tris-
HCl, 150 mmol/L NaCl, 0.1% SDS, 1% NP-40, 0.25% sodium
deoxycholate, and 1 mmol/L EDTA, pH 8.0). Proteins were sepa-
rated by SDS-PAGE. After electrophoresis, the proteins were elec-
trotransferred to PVDF membranes and then blocked with 5% skim
milk for 1 h. The membranes were then incubated with a primary
antibody against MTUS1 (Abcam, Cambridge, Mass) and GAPDH
(Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C for 12 h. After
three washes in TBST, the membranes were incubated with horse-
radish peroxidase-conjugated secondary antibody for 1 h at room
temperature. After three washes, the membranes were incubated
with the SuperSignal West Pico chemiluminescence substrate
(Pierce Biotechnology, USA).
Cell viability assay
A549 cells were plated at a density of 2 × 104 cells per well in 96-well
plates and then incubated overnight in DMEM supplemented with
10% FBS. Cells were collected at 12, 24, 48, and 72 h post-trans-
fection. After transfection, 10 mL of Cell CountingKit-8 solution
(#C0038, Beyotime, Jiangsu, China) was added to the appropriate
test wells and incubated for 1 h. Absorbance was measured at a
wavelength of 450 nm.
Transwell invasion assay
The migration ability of A549 cells was tested in a Transwell Boyden
Chamber (6.5-mm, Costar, USA). The polycarbonate membranes
(8-µm pore size) on the bottom of the upper compartment of the
Transwell chamber were coated with 1% human ﬁbronectin (R&D
systems 1918-FN, USA). The cells were harvested 24 h after
transfection and suspended in FBS-free DMEM. Then, the cells
were added to the upper chamber (4 × 104 cells/well). At the same
time, 0.5 mL of DMEM with 10% FBS was added to the lower
compartment, and the Transwell-containing plates were incubated
for 12 h in a 5% CO2 atmosphere saturated with H2O. After incu-
bation, the cells that had entered the lower surface of the ﬁlter
membrane were ﬁxed with 4% paraformaldehyde for 25 min at room
temperature, washed 3 times with distilled water and stained with
0.1% crystal violet in 0.1 mol/L borate and 2% ethanol for 15 min at
room temperature. Cells remaining on the upper surface of the ﬁlter
membrane (non-migrant) were scraped off gently with a cotton swab.
Images of the lower surfaces (with migrant cells) were captured by a
photomicroscope (5 ﬁelds per chamber) (BX51 Olympus, Japan),
and the cells were counted blindly.
Wound healing assays
Cell migration was assessed in a classical wound healing assay,
with some minor modiﬁcations. Brieﬂy, cells were seeded in 6-well
plates and transfected when they were attached. After transfection,
the cells were allowed to grow to conﬂuence. Then, the cell layer
was gently wounded using a plastic pipette tip (P200) and rinsed
with PBS before the culture medium was replaced. The bottoms of
the wells were marked to indicate where the initial images of the
wounded area were captured. After 24 h of incubation, images (10×)
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of the same areas were recorded using a photo microscope (BX51
Olympus, Japan), and wound closure was processed using Image-
Pro Plus 6.0.
Statistical analysis
All Western blotting, wound healing assay, and Transwell assay
images are representative of at least three independent experi-
ments. Quantitative RT-PCR and luciferase reporter assays were
performed in triplicate, and each experiment was repeated at least
three times. The results are presented as the mean ± SD. Differ-
ences between groups were calculated using Student’s t-test, and
P < 0.05 was considered statistically signiﬁcant.
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